Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bitopertin in EPP/XLP with Liver Disease
NCT07123363Phase 1Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2026
- Primary completion
- Dec 2035
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of bitopertin in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), sponsored by Wake Forest University Health Sciences. Primary endpoint: Number of treatment emergent adverse events at Week 104. Planned start Jan 2026; status: withdrawn.
02
Drugs
bitopertin
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NCT07123363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07123363.